Chemotherapy
Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review
Translational Lung Cancer Research 2025 October 31 [Link] Illaa Smesseim, Jo Raskin, Jacobus A Burgers Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The role of surgery in its management remains controversial, with ongoing debate regarding the definition of resectable disease. Neoadjuvant therapy aims to reduce tumor burden. This systematic review…
Read MoreUse of Patient-Derived Organoids for Pleural Mesothelioma 3D modelling
American Journal of Physiology Lung Cellular and Molecular Physiology 2025 October 29 [Link] Luca Volpini, Federica Monaco, Elisabetta Casalone, Elton Jalis Herman, Rebecca Filomena, Sandra Manzotti, Olga Strogovets, Gianluca Moroncini, Matteo Mozzicafreddo, Antonella Poloni, Elena Marinelli Busilacchi, Francesca Gonnelli, Francesca Barbisan, Gaia Goteri, Lina Zuccatosta, Martina Bonifazi, Giuseppe Matullo, Jiri Neuzil, Lory Santarelli, Najib M…
Read MoreDual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression
Cells 2025 October 15 [Link] Luca Hegedüs, Silvia Qaisieh, Christian Stülpnagel, Yavar Ganjeh Khor Dezfouli, Winny Tambo, Fabian Doerr, Natalie Baldes, Dirk Theegarten, Martin Schuler, Servet Bölükbas, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare cancer that often develops after a decades-long latency period and confers a grim prognosis. Novel, biomarker-based therapeutic modalities…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read MoreFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Journal of Experimental Clinical Cancer Research 2025 October 21 [Link] Ieman A M Aljahdali, Xiang Ling, Wenjie Wu, Wenchao Wang, Dan Li, Renyuan Zhang, Emma Zhang, Aimee Stablewski, Rami Azrak, Qingyong Li, Fengzhi Li Abstract Background: Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival time…
Read MoreResveratrol Affects Cell Activities, Induces Apoptosis and Regulates AMPK Signaling Pathway in Pleural Mesothelioma Cells
FASEB Journal 2025 October 31 [Link] Maria Rosa Iaquinta, Raffaella De Pace, Assia Benkhalqui, Cecilia Pesaresi, Simone Patergnani, Giulio Righes, Paolo Pinton, Mauro Tognon, Fernanda Martini, Elisa Mazzoni Abstract Pleural Mesothelioma (PM) is an aggressive tumor with a poor prognosis and limited therapeutic options. Despite the notion that resveratrol (RSV) significantly inhibits the growth of…
Read MoreA Rare Clinical Presentation of Malignant Pleural Mesothelioma With Central Nervous System Metastases: A Case Report
Cureus 2025 September 14 [Link] Magdalena A Miernik-Skrzypczak, Elwira Misztela-Lisiecka, Piotr Nowakowski, Anna Strozak, Grazyna Waska Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the pleural mesothelial cells, most often associated with long-term asbestos exposure. Symptoms are typically nonspecific, including shortness of breath, chest pain, and pleural effusion, which may…
Read MoreFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Journal of Experimental and Clinical Cancer Research 2025 October 21 [Link] Ieman A M Aljahdali, Xiang Ling, Wenjie Wu, Wenchao Wang, Dan Li, Renyuan Zhang, Emma Zhang, Aimee Stablewski, Rami Azrak, Qingyong Li, Fengzhi Li Abstract Background: Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival…
Read MoreGenetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma
Radiology and Oncology 2025 September 5 [Link] Matic Setina, Eva Setina, Ziga Doljak, Katja Goricar, Vita Dolzan, Viljem Kovac Abstract Background: Treatment of malignant mesothelioma (MM) still relies on chemotherapy with cisplatin in combination with pemetrexed or other drugs. Studies indicate that hypoxic conditions within tumour tissue may reduce responsiveness to cisplatin-based chemotherapy. Hypoxia-inducible factors…
Read More
Skip to content